drugset / Trial / NCT00149058

Erythropoietin in Acute Myocardial Infarction

NCT00149058

Phase 2 Unknown 124 enrolled Hammersmith Hospitals NHS Trust
RandomizedParallel-groupDouble-blindTreatment

Summary

Erythropoietin (EPO) is a naturally occuring hormone which regulates the body's response to lack of oxygen and controls the number of red cells in the blood. Recent studies in animals have shown that EPO has protective effects when organs such as the heart and brain are injured by lack of oxygen due to reduced blood supply. We wish to test the idea that giving a patient, who is having a heart attack, an injection of EPO will reduce the size of the heart attack.

Timeline

Start
2005-10
Primary completion
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 67000 iu Intravenous